Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication

Journal of the Neurological Sciences

Volumn 323, Issue 1-2, 2012, Pages 61-65

  Festoff, Barry W ^a   Li, Chaoyang ^b   Woodhams, Barry ^c   Lynch, Sharon ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c Diagnostica Stago R and D   (France)

Author keywords

Blood brain barrier; Clinical trial; Endothelial protein C receptor; Glatiramer acetate; Multiple sclerosis; Neuroprotection; Thrombomodulin

Indexed keywords

ENDOTHELIAL PROTEIN C RECEPTOR; GLATIRAMER; THROMBOMODULIN;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECEPTORS, CELL SURFACE; SOLUBILITY; THROMBOMODULIN;

EID: 84867884558     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.08.008     Document Type: Article

References (44)

1. A. Minagar, and J.S. Alexander Blood-brain barrier disruption in multiple sclerosis Mult Scler 9 2003 540 549
2. J.H. Griffin, J.A. Fernandez, L.O. Mosnier, D. Liu, T. Cheng, and H. Guo The promise of protein C Blood Cells Mol Dis 36 2006 211 216
3. A.K. Ohlin, K. Larsson, and M. Hansson Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma J Thromb Haemost 3 2005 976 982
4. O. Chazouilleres, M. Vaubourdolle, A. Robert, V. Fourel, P. Balladur, and A. Laribi Serum levels of endothelial injury markers creatine kinase-BB and soluble thrombomodulin during human liver transplantation Liver 16 1996 237 240
5. H. Takahashi, S. Ito, M. Hanano, K. Wada, H. Niwano, and Y. Seki Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator Am J Hematol 41 1992 32 39
6. H. Weiler, and B.H. Isermann Thrombomodulin J Thromb Haemost 1 2003 1515 1524
7. C.T. Esmon, and W.G. Owen The discovery of thrombomodulin J Thromb Haemost 2 2004 209 213
8. C.T. Esmon Protein C pathway in sepsis Ann Med 34 2002 598 605
9. P.C.Y. Liaw, P.F. Neuenschwander, M.D. Smirnov, and C.T. Esmon Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function J Biol Chem 275 8 2000 5447 5452
10. F. Califano, T. Giovanniello, P. Pantone, E. Campana, C. Parlapiano, and F. Alegiani Clinical importance of thrombomodulin serum levels Eur Rev Med Pharmacol Sci 4 2000 59 66
11. N. Tsukada, M. Matsuda, K. Miyagi, and N. Yanagisawa Thrombomodulin in the sera of patients with multiple sclerosis and human lymphotropic virus type-1-associated myelopathy J Neuroimmunol 56 1995 113 116
12. S. Frigerio, C. Ariano, G. Bernardi, E. Ciusani, G. Massa, and L. La Mantia Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients J Neuroimmunol 87 1998 88 93
13. C.D. Hsu, D.W. Chan, B. Iriye, T.R. Johnson, S.F. Hong, and M. Petri Plasma thrombomodulin levels in women with systemic lupus erythematosus Am J Perinatol 12 1995 27 29
14. C.A. Sesin, X. Yin, C.T. Esmon, J.P. Buyon, and R.M. Clancy Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence Kidney Int 68 2005 110 120
15. T.K. Nilsson, K. Boman, J.H. Jansson, A.M. Thogersen, M. Berggren, and A. Broberg Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at - 70 degrees C for 8-11 years Thromb Res 116 2005 249 254
16. V. Salomaa, and K.K. Wu Soluble thrombomodulin as predictor of incident coronary heart disease Lancet 354 1999 1646 1647
17. J. Amiral, M. Adam, F. Mimilla, I. Larrivaz, B. Chambrette, and M.C. Boffa Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma Hybridoma 13 1994 205 213
18. A. Bitsch, and W. Bruck Differentiation of multiple sclerosis subtypes: implications for treatment CNS Drugs 16 2002 405 418
19. S.B. Patten, L.M. Metz, and For the SPECTRIMS Study Group Interferon b1a and depression in secondary progressive MS: data from the SPECTRIMS trial Neurology 59 2002 744 746
20. J.S. Wolinsky, P.A. Narayana, P. O'Connor, P.K. Coyle, C. Ford, and K. Johnson Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial Ann Neurol 61 2007 14 24
21. C. Lucchinetti, W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 2000 707 717
22. J.N. Whitaker Myelin basic protein in cerebrospinal fluid and other body fluids Mult Scler 4 1998 16 21
23. M. Zaffaroni Biological indicators of the neurodegenerative phase of multiple sclerosis Neurol Sci 24 2003 S279 S282
24. A.R. Massaro, and P. Tonali Cerebrospinal fluid markers in multiple sclerosis: an overview Mult Scler 4 1998 1 4
25. C.M. Pelfrey, R.A. Rudick, A.C. Cotleur, J.C. Lee, M. Tary-Lehmann, and P.V. Lehmann Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production J Immunol 165 2000 1641 1651
26. F. Sellebjerg, C.V. Jensen, and M. Christiansen Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis J Neuroimmunol 108 2000 207 215
27. T. Kohriyama, H. Maruyama, K. Kurokawa, T. Harada, and S. Nakamura Endothelial cell activation and/or injury in multiple sclerosis: analysis with von Willebrand factor and thrombomodulin Rinsho Shinkeigaku 37 1997 287 291
28. M. Menschikowski, A. Hagelgans, G. Eisenhofer, O. Tiebel, and G. Siegert Reducing agents induce thrombomodulin shedding in human endothelial cells Thromb Res 126 2010 e88 e93
29. K. Suzuki, J. Nishioka, T. Hayashi, and Y. Kosaka Functionally active thrombomodulin is present in human platelets J Biochem 104 4 1988 628 632
30. P.C. Liaw Endogenous protein C activation in patients with severe sepsis Crit Care Med 32 2004 S214 S218
31. R. Deane, B. LaRue, A.P. Sagare, F.J. Castellino, Z. Zhong, and B.V. Zlokovic Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier J Cereb Blood Flow Metab 29 2009 25 33
32. R. Aharoni, R. Arnon, and R. Eilam Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis J Neurosci 25 2005 8217 8228
33. O. Khan, Y. Shen, C. Caon, F. Bao, W. Ching, and M. Reznar Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis Mult Scler 11 2005 646 651
34. O. Khan, F. Bao, M. Shah, C. Caon, A. Tselis, and R. Bailey Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study J Neurol Sci 312 1-2 2012 7 12
35. R. Aharoni, R. Eilam, H. Domev, G. Labunskay, M. Sela, and R. Arnon The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice Proc Natl Acad Sci U S A 102 2005 19045 19050
36. H. Lassmann, G. Suchanek, and K. Ozawa Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis Ann Neurol 36 1994 S42 S46 [Suppl.]
37. J. Plumb, S. McQuaid, M. Mirakhur, and J. Kirk Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis Brain Pathol 12 2002 154 169
38. A. Minagar, D. Ostanin, A.C. Long, M. Jennings, R.E. Kelley, and M. Sasaki Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells Mult Scler 9 2003 235 238
39. E.M. Conway, M. Van de Wouwer, S. Pollefeyt, K. Jurk, H. Van Aken, and A. De Vriese The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways J Exp Med 196 2002 565 577
40. T. Ito, and I. Maruyama Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation J Thromb Haemost 9 Suppl. 1 2011 168 173
41. F.S. Orhon, H. Ergun, Y. Egin, B. Ulukol, S. Baskan, and N. Akar Soluble endothelial protein C receptor levels in healthy population J Thromb Thrombolysis 29 2010 46 51
42. C.T. Esmon Structure and functions of the endothelial cell protein C receptor Crit Care Med 32 2004 S298 S301
43. M.O. Giwa, J. Williams, K. Elderfield, N.S. Jiwa, L.R. Bridges, and R.N. Kalaria Neuropathologic evidence of endothelial changes in cerebral small vessel disease Neurology 78 2012 167 174
44. M. Fisher Thrombomodulin and the brain: past, present, and future Neurology 78 3 2012 157 158